Allianz Safety and Shipping Review 2024: 26 large ships lost worldwide in 2023, down by one third year-on-year, the industry's lowest ever total War and geopolitical conflicts shake up the
1Q24 Revenue of $68.6 million at the high end of the guidance range. 1Q24 Non-GAAP Operating Income of $4.4 million or 6% compared to a loss of million or in 1Q23.Record high Free Cash Flow of $16.6.
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U S marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and